1. Scrip
  2. >>Business

Biopharma Funding Contracted Last Year – And 2023 Will See The Squeeze Continue

Up To 300 Companies Could Seek New Funds This Year

 
• By Andrew McConaghie

Now the pandemic-era biotech boom is over, biopharma companies and investors are both adjusting their financing strategies to survive and even thrive in the new environment.

Scrip Perspectives 2023
After the boom years of 2020 and 2021, the environment turned difficult for many early-stage biotechs last year, and 2023 could be even more challenging. • Source: Shutterstock

After the COVID-19 pandemic induced rush into biopharma investing seen during 2020 and 2022, last year saw a big drop-off in investment into the sector, new data show.

The total number of financing deals (excluding M&A and licensing deals) more than doubled in 2020 and hit a peak of 1,426 the following year, but dropped back to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip